← The Wire·Regulation·

BioLife Solutions merger with Repligen advances as antitrust waiting period ends

BioLife Solutions’ merger with Repligen has cleared the U.S. antitrust waiting period, removing one procedural hurdle to the transaction. The setup now shifts to the remaining closing conditions and whether the combination can add to Repligen’s growth without worsening its already modest profitability.

STOCK PHOTO · DAVID DIBERT

The story

The antitrust waiting period for BioLife Solutions' proposed merger with Repligen has ended. The development moves the deal beyond one U.S. competition-law checkpoint, but it is not the same as completion. The next meaningful updates should establish the closing timetable and any remaining approvals or conditions.

Repligen reported fiscal-year 2025 revenue of $738.3 million, up 16.4% year over year, with diluted EPS of $0.86 and net margin of 6.6%. Those figures provide the operating base against which investors will judge the strategic and financial contribution of BioLife Solutions, but they do not establish the merger's expected synergies or financing impact.

The next concrete markers are the companies' closing announcement and any filings describing the remaining conditions, purchase accounting, financing or expected contribution from BioLife Solutions. Repligen's next earnings disclosure should also show whether its 2025 growth trajectory and 6.6% net margin are holding as the transaction advances.

Our read · Thu, Sep 10

The antitrust clearance removes a deal hurdle for RGEN, but the financial payoff remains unquantified and the closing path is still the key risk.

Why. The immediate benefit is procedural: antitrust clearance lowers one barrier to Repligen’s acquisition. Repligen’s FY2025 revenue growth of 16.4% is a concrete operating backdrop, while its 6.6% net margin leaves the eventual earnings contribution and integration costs important unresolved variables.

Both cases

The case it holdsThe merger advances without a disclosed antitrust objection, while Repligen’s FY2025 revenue grew 16.4%, giving the combined company a credible operating-growth base.
The case it breaksRepligen’s 6.6% net margin leaves room for integration costs to dilute the benefit.

What could change this view: The trade read fails if another approval, shareholder condition or transaction term delays or changes the merger, or if subsequent filings show limited synergies or added costs.

Repligen stock page →
Your side is graded privately against closes after 10 trading days. Research, not advice.

Who reported it · 1

Keep reading

Latest on the Wire

Trump threatens overseas AI data-centre ban for US firmsBitcoin drops below $59,000 as cash rush revives summer-low testGreer says US chip curbs will close China export-control loopholesBlackRock bitcoin ETF posts $541.1 million outflow as tech sell-off spreadsPoland says Russian missiles and drone crashed during Ukraine assaultContinue on the Wire →

Top this week

Nvidia allies lobby board to bring back Jensen Huang as CEONvidia chair rules out Huang return as CEO after 75% sales outlookAnthropic Said to Guide IPO Pricing Above Market RangeNvidia interim CEO Colette Kress faces first earnings test after HuangAnthropic IPO could become the largest in US history on Thursday
The Wire at 7 AM ET, free. Top stories with a bull and a bear case on each, every morning. No account needed.

About this report

Reported by Investing.com, . Who answers for this

The only report in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →

Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →